Clinical Pharmacology Characterization and Dose Selection of Xaluritamig, a Next Generation XmAb® 2+1 T-Cell Engager, in Prostate Cancer Patients.
Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose...
https://pubmed.ncbi.nlm.nih.gov/40765197/Actively Recruiting
Led by Amgen · Updated on 2026-08-21
479
Participants Needed
57
Research Sites
104 weeks
Total Duration
Researchers are evaluating AMG 509 in people with metastatic castration-resistant prostate cancer mCRPC to assess its safety, tolerability, how the body processes the drug, and preliminary effectiveness. The study includes participants who have received various prior treatments such as novel hormonal therapies and taxane chemotherapy. This is a Phase 1 trial with multiple parts, including expansion cohorts, some of which are open for enrollment as of July 2025. The trial tests AMG 509 given either as an intravenous IV infusion or subcutaneous SC injection, alone or combined with oral drugs abiraterone acetate or enzalutamide. Different parts of the study focus on different patient groups and dosing strategies, including dose exploration to find the maximum tolerated dose and recommended phase 2 dose. Some parts also examine AMG 509 given in outpatient infusion centers, with specific cohorts enrolled in China to confirm safety and dosing. Participants undergo screening to confirm eligibility, followed by treatment phases where AMG 509 and combinations are administered according to assigned study parts. Throughout the study, safety is monitored by tracking adverse events, vital signs, ECGs, and lab tests over several years. Effectiveness is assessed using tumor response criteria, prostate-specific antigen levels, and imaging studies. The trial includes long-term follow-up to evaluate treatment outcomes and pharmacokinetics over up to three years.
CONDITIONS
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
A
Amgen Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Amgen
Lead Sponsor
BeiGene
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | AMG 509 (multiple cohorts by administration route and combination) | Abiraterone or Enzalutamide + Androgen Deprivation (Current Care) |
|---|---|---|
| What is it? | Experimental T-cell engaging bispecific antibody (xaluritamig/AMG 509) targeting STEAP1 and CD3, tested as IV or SC monotherapy and with abiraterone or enzalutamide in several sequential cohorts. | Hormone-based oral therapy (abiraterone or enzalutamide) plus ongoing androgen deprivation therapy, recommended as current standard of care for men with mCRPC post-taxane. |
| Role in the study | Investigational treatment; enrolled cohorts test safety, dose-finding, and selected combinations in eligible mCRPC patients. | Reference for current-practice therapy outside the trial. Not randomized in the study. |
| Primary use or clinical goal | Potential treatment for mCRPC with progression after standard therapies. Investigated to assess anti-tumor activity, safety, and dose selection. | Slows tumor progression, reduces prostate-specific antigen (PSA) levels, and improves survival for mCRPC after prior therapies. |
| How is it given or performed? | AMG 509 is administered as an intravenous infusion or subcutaneous injection, with some cohorts also receiving oral abiraterone or enzalutamide. Dosing schedules vary by cohort. | Abiraterone or enzalutamide taken as daily oral tablets, combined with ongoing hormone therapy (ADT; injections or implants). |
| Evidence status | Early-stage clinical data available from dose escalation/expansion phases, showing initial signals of anti-tumor activity and establishing safety for AMG 509 in mCRPC. Larger confirmatory studies pending. | Extensive published evidence supports abiraterone and enzalutamide with ADT as standards for improving survival and delaying progression in mCRPC after taxane/previous hormonal therapy. |
| Key limitations | Single-group sequential cohorts with no concurrent control arm; real-world benefit/risk cannot be fully established. Longer-term safety and efficacy versus current therapies remain unproven. | Outcomes can be limited by eventual treatment resistance, adverse effects, and progression despite therapy. Access or suitability for abiraterone/enzalutamide may be affected by prior therapy or health status. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit (in-person)
Duration - Up to 3 years
Participants receive AMG 509 as intravenous infusion or subcutaneous injection, alone or combined with abiraterone acetate or enzalutamide, depending on their assigned study part. Dosing schedules and combinations vary by cohort and treatment phase.
Regular visits for drug administration and monitoring
Duration - Up to 3 years
Participants are monitored for safety, treatment response, and drug levels through laboratory tests, imaging scans, and clinical assessments over several years after treatment completion.
Periodic visits for assessments and safety monitoring
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
7
Have more questions? Get in touch with our team for quick support
Jamie N Kuipers-Connarn, Arya Pourzanjani, Maitreyee Bose...
https://pubmed.ncbi.nlm.nih.gov/40765197/William K Kelly, Daniel C Danila, Chia-Chi Lin...
https://pubmed.ncbi.nlm.nih.gov/37861461/Amgen
Lead Sponsor
BeiGene
Collaborating Sponsor